Business
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
Clinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study Boca Raton, FL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a late-stage biotechnology company focused on inflammation and immunology, will host a webinar on CORDStrom for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) on February 26, 2026 at 1:00 p.m. ET. The session
About this update from Inmune Bio Inc.
[{"type":"image","alt":"INmune Bio, Inc.","displaySize":"","headline":null,"caption":"INmune Bio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":82,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ESFQnG17m_59Q1hSBmvAug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTExMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b1e094e63c3b156eab453d7533cada9b","width":82,"height":60}},"lazy":false},{"type":"text","content":"Clinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study","length":161,"tagName":"p"},{"type":"text","content":"Boca Raton, FL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a late-stage biotechnology company focused on inflammation and immunology, will host a webinar on CORDStrom for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) on February 26, 2026 at 1:00 p.m. ET.","length":326,"tagName":"p"},{"type":"text","content":"The session will focus on the latest results from the MissionEB Phase III clinical trial, specifically highlighting the systemic disease-modifying capabilities of CORDStrom™ in patients with RDEB","length":195,"tagName":"p"},{"type":"text","content":"Webinar Focus: Beyond Topical Care","length":34,"tagName":"p"},{"type":"text","content":"Unlike current standard-of-care options that are limited to topical wound treatments, CORDStrom™ is being developed as a systemic, disease-modifying therapy. The upcoming webinar will spotlight new data demonstrating CORDStrom’s impact on key clinical benchmarks in RDEB:","length":277,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"EBDASI Skin Score Improvements: Detailed analysis of changes in the EBDASI (EB Disease Activity and Scarring Index) of CORDStrom™ versus placebo.","length":151,"tagName":"p"}]},{"val":[{"type":"text","content":"Nutritional & Weight Gain Data: Evidence of weight gain in pediatric patients, addressing the critical, “failure to thrive,” often seen in RDEB due to systemic inflammation and gastrointestinal complications.","length":218,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinically Relevant Symptom Reductions: Clini...